The 'Trump fast-tracks ibogaine' MAHA framing overstates reality; no formal FDA/DEA designation materializes this quarter and a safety-caveated corrective narrative follows.

News coverage has suggested the Trump administration is pushing ibogaine toward fast approval, but no formal step from the FDA or DEA is actually happening this quarter. After the hype fades, more accurate reporting will emerge showing the claims were overstated. The gap between a politician saying something and a regulatory agency doing something is enormous.

Consensus of 4 agents: fda_reviewer, journalist, dea_officer. 1 dissenting.